This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Labcorp is now offering a blood-based biomarker test in ...

BURLINGTON, N.C. - Labcorp (NYSE:LH), a prominent healthcare diagnostics provider with a market capitalization of $23.5 billion, announced Thursday it will offer the Elecsys pTau181 test nationwide by ...

BURLINGTON, N.C. - Labcorp (NYSE:LH), a prominent $22.5 billion healthcare services provider with a strong financial health rating according to InvestingPro, announced Monday the nationwide ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

(Reuters) - Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the ...

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care Alzheimer's disease, the most prevalent form of dementia, poses a ...

BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...

BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...

Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...